Abstract
Osteoporotic fractures, particularly hip fractures, can have a devastating impact on the well-being of the elderly population. Recently, two population-based observational studies reported a highly important association between the use of potent acid suppressive therapy and an increased risk of hip fractures. The mechanisms underlying such an association are not clear. However, a careful review of the existing evidence seems to suggest that the main physiologic consequences of proton pump inhibitor therapy may each have a theoretical influence on bone metabolism. Specifically, inhibition of the osteoclastic proton pumps may reduce bone resorption, while profound acid suppression could potentially hamper intestinal calcium absorption, and secondary hypergastrinemia may enhance bone resorption through the induction of parathyroid gland hyperplasia. However, the existing data are clearly too limited for us to draw any definitive conclusions, and more studies are urgently needed to delineate the physiologic relevance of these theoretical mechanistic links, individually and collectively.
Keywords: Osteoporosis, Proton Pump Inhibitor, metabolism, hypergastrinemia, parathyroid gland
Current Drug Safety
Title: Proton Pump Inhibitor Therapy and Osteoporosis
Volume: 3 Issue: 3
Author(s): Yu-Xiao Yang
Affiliation:
Keywords: Osteoporosis, Proton Pump Inhibitor, metabolism, hypergastrinemia, parathyroid gland
Abstract: Osteoporotic fractures, particularly hip fractures, can have a devastating impact on the well-being of the elderly population. Recently, two population-based observational studies reported a highly important association between the use of potent acid suppressive therapy and an increased risk of hip fractures. The mechanisms underlying such an association are not clear. However, a careful review of the existing evidence seems to suggest that the main physiologic consequences of proton pump inhibitor therapy may each have a theoretical influence on bone metabolism. Specifically, inhibition of the osteoclastic proton pumps may reduce bone resorption, while profound acid suppression could potentially hamper intestinal calcium absorption, and secondary hypergastrinemia may enhance bone resorption through the induction of parathyroid gland hyperplasia. However, the existing data are clearly too limited for us to draw any definitive conclusions, and more studies are urgently needed to delineate the physiologic relevance of these theoretical mechanistic links, individually and collectively.
Export Options
About this article
Cite this article as:
Yang Yu-Xiao, Proton Pump Inhibitor Therapy and Osteoporosis, Current Drug Safety 2008; 3 (3) . https://dx.doi.org/10.2174/157488608785699414
DOI https://dx.doi.org/10.2174/157488608785699414 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Essential Fatty Acids - A Review
Current Pharmaceutical Biotechnology Lipoxins, The Novel Mediators of Gastroprotection and Gastric Adaptation to Ulcerogenic action of Aspirin
Current Pharmaceutical Design Validation of Acute Liver Injury Cases in a Population-Based Cohort Study of Oral Antimicrobial Users
Current Drug Safety Polysaccharides as Bacterial Antiadhesive Agents and “Smart” Constituents for Improved Drug Delivery Systems Against Helicobacter pylori Infection
Current Pharmaceutical Design Therapeutic Potential of Targeting TREM-1 in Inflammatory Diseases and Cancer
Current Pharmaceutical Design Expression and Single Nucleotide Polymorphism of Poly (ADPRibose) Polymerase-1 in Gastrointestinal Tumours: Clinical Involvement
Current Medicinal Chemistry Bisthiourea Derivatives of Dipeptide Conjugated Benzo[d]isoxazole as a New Class of Therapeutics: Synthesis and Molecular Docking Studies
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry IgE-Mediated Disorders: Current Therapeutics and New Strategies Involving Synthetic Peptides
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Angiogenic and Anti-Angiogenic Therapy for Gastrointestinal Ulcers: New Challenges for Rational Therapeutic Predictions and Drug Design
Current Pharmaceutical Design Applications of luminous bacteria enzymes in toxicology
Combinatorial Chemistry & High Throughput Screening Pharmacokinetic and Pharmacodynamic Variability: A Daunting Challenge in Drug Therapy
Current Drug Metabolism Hydrogel-clay Nanocomposites as Carriers for Controlled Release
Current Medicinal Chemistry Understanding the Concept of Chronotherapeutics in the Management of Diabetes Mellitus
Current Diabetes Reviews Cardiovascular and Renovascular Implications of COX-2 Inhibition
Current Pharmaceutical Design Cerebral Palsy: Classification, Etiology and Evolution of Spine Deformity in Children and Adolescents
Current Pediatric Reviews Is Helicobacter pylori Always a "Bad Guy"?
Current Pharmaceutical Design Immunomodulation in Inflammatory Neuropathies: Rationale and Safety
Current Drug Safety A Rare Cause of Upper Gastrointestinal Bleeding in Children: Gastric Schwannoma
Current Pediatric Reviews Mucosal Immune Regulation and Vaccines for Helicobacter-associated Gastritis
Current Chemical Biology The Transthyretin Inflammatory State Conundrum
Current Nutrition & Food Science